Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2007

NanoInk Receives Patent Rights from Arrowhead Research

  • Arrowhead Research exclusively licensed intellectual property to NanoInk. The patent application covers techniques related to use of surfactants to support NanoInk’s Dip Pen Nanolithography® (DPN®) technology. DPN involves deposition of nanoscale materials onto a substrate.

    Arrowhead’s technology was developed through its sponsored research at the laboratory of Patrick Collier, Ph.D., at the California Institute of Technology.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »